BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 20592067)

  • 1. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
    Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
    Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.
    Fareau GG; Lopez A; Stava C; Vassilopoulou-Sellin R
    Anticancer Drugs; 2008 Jul; 19(6):637-44. PubMed ID: 18525324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic chemotherapy for adrenocortical carcinoma.
    Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
    Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
    Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
    Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive treatment of adrenocortical carcinoma.
    Terzolo M; Berruti A
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A; Li Y; Forastiere A
    Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial.
    Redlich A; Boxberger N; Strugala D; Frühwald MC; Leuschner I; Kropf S; Bucsky P; Vorwerk P
    Klin Padiatr; 2012 Oct; 224(6):366-71. PubMed ID: 23143764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.
    Luton JP; Cerdas S; Billaud L; Thomas G; Guilhaume B; Bertagna X; Laudat MH; Louvel A; Chapuis Y; Blondeau P
    N Engl J Med; 1990 Apr; 322(17):1195-201. PubMed ID: 2325710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of platinum analogue-based chemotherapy for advanced esophageal squamous cell carcinoma and prognostic factors].
    Yang L; Wang JW; Shi YK
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1233-7. PubMed ID: 21756792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.